Dasiglucagon

InChIKey
RZRMFQMNPDPAIX-AJTOSFMRSA-N

SMILES
C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)NC(C)(C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC4=CC=CC=C4)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC5=CNC6=CC=CC=C65)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)CNC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC7=CNC=N7)N)O

• In children with CHI, skin events were more frequent with dasiglucagon plus standard care than standard care alone. (The Journal of clinical endocrinology and metabolism, 2024)
• Nausea was numerically more frequent with dasiglucagon than oral glucose, without a significant difference. (Diabetes care, 2022)
• Nausea occurred more often with dasiglucagon than with identical doses of commercial glucagon. (Diabetes, obesity & metabolism, 2019)
• Nausea rates were similar with dasiglucagon and GlucaGen. (Diabetes care, 2018)
• In healthy volunteers, dasiglucagon had no clinically relevant effect on heart rate compared with placebo. (Current therapeutic research, clinical and experimental, 2022)
• The repeated-dose dasiglucagon trial detected no new or increased antidrug antibodies. (Diabetes technology & therapeutics, 2021)
• The dasiglucagon trial reported no serious adverse events. (Diabetes, obesity & metabolism, 2021)
• In individuals after gastric bypass, dasiglucagon was generally well tolerated. (Diabetes care, 2023)
• In adults with type 1 diabetes, low-dose dasiglucagon was safe and well tolerated. (Diabetologia, 2023)
• In infants, frequent adverse events in both groups included gastrointestinal, skin, and metabolism and nutritional disorders. (The Journal of clinical endocrinology and metabolism, 2025)
• A neonate developed necrolytic migratory erythema during prolonged dasiglucagon therapy. (Endocrinology, diabetes & metabolism case reports, 2025)
• The adolescent with suspected insulinoma tolerated dasiglucagon. (Hormone research in paediatrics, 2024)
• In adults with type 1 diabetes, dasiglucagon had similar safety and tolerability to reconstituted glucagon. (Diabetes, obesity & metabolism, 2023)
• In children with CHI, gastrointestinal events were more frequent with dasiglucagon plus standard care than standard care alone. (The Journal of clinical endocrinology and metabolism, 2024)
• Reported adverse effects did not differ significantly between dasiglucagon and oral glucose. (Diabetes care, 2022)
• Vomiting occurred more often with dasiglucagon than with identical doses of commercial glucagon. (Diabetes, obesity & metabolism, 2019)
• In healthy volunteers, dasiglucagon had no clinically relevant effect on the heart's PR interval compared with placebo. (Current therapeutic research, clinical and experimental, 2022)
• In healthy volunteers, dasiglucagon had no clinically relevant effect on the heart's QRS duration compared with placebo. (Current therapeutic research, clinical and experimental, 2022)
• In healthy volunteers, dasiglucagon produced minor QTcF prolongation without clear dose or concentration dependency. (Current therapeutic research, clinical and experimental, 2022)
• In healthy volunteers, both models placed placebo-corrected QTcF changes below the regulatory threshold, although the linear model fit poorly at low concentrations. (Current therapeutic research, clinical and experimental, 2022)
• In healthy volunteers, the modeled maximum dasiglucagon QTcF effect was 3.6 ms compared with placebo. (Current therapeutic research, clinical and experimental, 2022)
• In healthy volunteers, the dasiglucagon treatment effect-specific intercept was -0.44 ms. (Current therapeutic research, clinical and experimental, 2022)
• The dasiglucagon trial reported no unexpected safety findings. (Diabetes technology & therapeutics, 2021)
• In individuals after gastric bypass, dasiglucagon adverse events included mostly mild to moderate nausea. (Diabetes care, 2023)

The doses that these studies used. They are not recommendations.